Tuesday, 12 January 2021

(Post 239/Yr 4 wk 18)Company Report:ARK Investment Management Daily Trades 12/18/2020


Kasplkz JSC

As this is an london stock,we will skip it


Teladoc Health, Inc. provides virtual healthcare services. The Company provides virtual access to care with a portfolio of services and solutions, which includes various medical subspecialties from non-urgent, episodic needs, such as flu and upper respiratory infections, to chroniccomplicated medical conditions, such as cancer and congestive heart failure. It provides virtual healthcare services on a business-to-business (B2B) basis to its clients and provides services to consumers directly and through channel partners. The Company’s consumer brands, including TeladocAdvance MedicalBest DoctorsBetterHelp and HealthiestYou, provides access to advice and resolution to a range of healthcare needs. Its technology enables consumers to manage their own electronic medical records. It also provides access to a message center, provider finderimage upload capability and enable real-time sharing capabilities with providers that includes visit scheduling.

Day Range Brought:191.60-198.55

Takeda Pharmaceutical Company Limited

Takeda Pharmaceutical Company Limited is a Japan-based company mainly engaged in the pharmaceutical business. The Company is engaged in the research, development, manufacture and sale of pharmaceutical products, General medical products, quasi drugs and healthcare products in Japan and overseas. The Company's research and development functions are concentrated in four areas of oncology (cancer), digestive system diseases, rare diseases and neurology (neuropsychiatric diseases), as well as two business units of plasma fractionation products and vaccines. The Company is engaged in the improvement of pipelines at research and development centers located mainly in Japan and the United States.

Day Range Brought:18.81-19.09

Surface Oncology

Surface Oncology, Inc. is a clinical-stage immuno-oncology company. The Company is engaged in the development of cancer immunotherapies. To unlock the potential of cancer immunotherapy, the Company is targeting a set of immune processes by which cancer cells evade immune recognition and attack. Its programs are built upon insights about how to improve the immune system’s recognition and elimination of cancer cells. These include approaches to improve the effectiveness of antigen presentation to the adaptive immune system, to block the activity of a range of suppressor cells in the tumor microenvironment, and to counter the immunosuppressive environment that selectively accumulates in and around the tumor. By targeting the interface of innate and adaptive immunity, it hopes to expand the reach of cancer immunotherapy to patients in need of treatment.

Day Range Brought:8.95-9.85

Schrodinger Inc

Schrodinger, Inc. provides computational software solutions for drug discovery to the biopharmaceutical industry. The Company operates through two segments: Software and Drug Discovery. The Software segment is focused on licensing the Company’s software for molecular discovery. The Drug Discovery segment is focused on building a portfolio of preclinical and clinical drug programs, internally and through collaborations. Its platform integrates solutions for predictive modeling, data analytics and collaboration. Its wholly-owned programs include SDGR1, SDGR2, SDGR3, SDGR4 and SDGR5. SDGR1 and SDGR2 drug discovery programs are focused on targets that mediate deoxyribonucleic acid (DNA) repair, cell cycle regulation, replication stress responses, and apoptosis, or programmed cell death. SDGR3, SDGR4 and SDGR5 drug discovery programs are focused on genetically-defined cancers.

Day Range Brought:78.12-81.31

Ionis pharmaceuticals

Ionis Pharmaceuticals, Inc. is engaged in discovering and developing ribonucleic acid (RNA)-targeted therapeutics. The Company, using its drug discovery platform, has developed a pipeline of drugs for patients with unmet medical needs. The Company's segments include Ionis Core and Akcea Therapeutics. In the Ionis Core segment, the Company is engaged in exploiting a drug discovery platform to generate a pipeline of drugs for the Company and its partners. The Akcea Therapeutics segment includes the operations of the Company's subsidiary, Akcea Therapeutics, Inc. (Akcea Therapeutics). Akcea Therapeutics is focused on developing and commercializing volanesorsen and other clinical-stage drugs for serious cardiometabolic diseases caused by lipid disorders. The Company is developing volanesorsen to treat two severe and rare, genetically defined diseases, familial chylomicronemia (FCS) and familial partial lipodystrophy (FPL). The Company offers SPINRAZA, a Generation 2.0+ antisense drug

Day Range Brought:51.46-54.57

Incyte Corporation

Incyte Corporation is a biopharmaceutical company focused on the discovery, development and commercialization of therapeutics. Its portfolio includes compounds in various stages, ranging from preclinical to late-stage development, and commercialized products, such as JAKAFI (ruxolitinib) and ICLUSIG (ponatinib). JAKAFI (ruxolitinib) is indicated for the treatment of patients with intermediate or high risk myelofibrosis (MF) and for the treatment of patients with polycythemia vera (PV) having had an inadequate response to or are intolerant of hydroxyurea. As of December 31, 2016, the Food and Drug Administration had granted JAKAFI orphan drug status for MF, PV and essential thrombocythemia. The primary target for ICLUSIG is B Cell Receptor-ABL, an abnormal tyrosine kinase that is expressed in chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia. The Company also has a portfolio of selective janus associated kinases 1 (JAK1) inhibitors.

Day Range Brought:87.43-89.34

Codexis Inc

Codexis, Inc. is a protein engineering company. The Company is engaged in the development of biocatalysts for the commercial manufacture of pharmaceuticals and fine chemicals. The Company operates through its two segments, such as the performance enzymes and novel biotherapeutics. It provides enzyme optimization services from small scale through to commercial quantities and also develops biocatalyst products. It is also engaged in the development of manufacturing processes for active pharmaceutical ingredients, fine chemicals and food ingredients. Its CodeEvolver is a protein engineering technology platform and products in the pharmaceuticals market. The Company serves various industries, including food and food ingredients, animal feed, flavors, fragrances, and agricultural chemical.

Day Range Brought:19.48-20.43

Berkeley Lights Inc

Berkeley Lights, Inc. is a Digital Cell Biology company focused on enabling and accelerating the rapid development and commercialization of biotherapeutics and other cell-based products. The Company has developed the Berkeley Lights Platform to provide the advanced environment for rapid functional characterization of single cells at scale. The Berkeley Lights Platform consists of advanced automated systems that analyze live cells using consumables and application and workflow software to deliver robust single cell data. Its platform characterizes the performance of cells relevant to the desired cell-based product early in the process and then connects this phenotypic data to the genetic code for each cell. The Berkeley Lights Platform is a fully integrated, end-to-end solution, comprised of consumables, including its OptoSelect chips and reagent kits, advanced automation systems and advanced application and workflow software.

Day Range Brought:89.29-94.97


CRISPR Therapeutics AG is a Switzerland-based gene-editing company. It focuses on the development of transformative gene-based medicines for serious diseases. The Company develops its products using Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/Cas9 gene-editing platform, which allows for precise directed changes to genomic deoxyribonucleic acid (DNA). The Company has a portfolio of therapeutic programs in a range of disease areas, including hemoglobinopathiesoncologyregenerative medicine and rare diseases. Its lead product candidate is CTX001, an ex vivo CRISPR gene-edited therapy for treating patients suffering from transfusion-dependent beta thalassemia or severe sickle cell disease in which a patient’s hematopoietic stem cells are engineered to produce high levels of fetal hemoglobin in red blood cells. The Company has business operations in London and the United Kingdom, as well as research and development operations in the United States.

Day Range Sold:147.00-151.87

Arcturus Therapeutics Holdings Inc

Arcturus Therapeutics Holdings Inc. is a clinical-stage messenger ribonucleic acid (mRNA) medicines and vaccines company. The Company’s technologies include LUNAR lipid-mediated deliverySTARR mRNA Technology and mRNA drug substance along with drug product manufacturing. Its pipeline of ribonucleic acid (RNA) therapeutic candidates include programs to treat ornithine transcarbamylase (OTC) deficiencycystic fibrosis, glycogen storage disease type threehepatitis Bnon-alcoholic steatohepatitis (NASH) and a self-replicating mRNA vaccine for severe acute respiratory syndrome coronavirus two (SARS-CoV-2). Its RNA therapeutics platforms have applications in types of nucleic acid medicines, including messenger RNA, small interfering RNA, replicon RNA, antisense RNA, microRNA, deoxyribonucleic acid (DNA) and gene editing therapeutics. The Company is focused on liver and respiratory diseases.

Day Range Sold:95.17-104.13

Unity Software Inc

Unity Software Inc. (Unity) is a platform for creating and operating interactive, real-time three-dimensional content. The platform provides a set of software solutions to create, run and monetize interactive, real-time two-dimensional (2D) and three-dimensional (3D) content for mobile phones, tablets, personal computers, consoles, and augmented and virtual reality devices. Content made with Unity is real-time, allowing it to instantly adapt to user's behavior and feedback. Unity’s Create Solutions are used by content creators, developers, artists, designers, engineers, and architects to create interactive, real-time 2D and 3D content. The Company’s Operate Solutions offers customers the ability to engage their end-user base, as well as run and monetize their content.

Day Range Brought:151.09-158.36

Exone Co/The

ExOne Co is a provider of three dimension (3D) printing machines and 3D printed and other products, materials and services to industrial customers. The Company’s business primarily consists of manufacturing and selling 3D printing machines and printing products to specification for its customers using its installed base of 3D printing machines. It also supplies the associated materials, including consumables and replacement parts, and other services, including training and technical support, that are necessary for purchasers of its 3D printing machines to print products. The Company’s 3D printing machines build or print products from computer-aided drafting (CAD) models by depositing successive thin layers of particles of materials, such as silicate sands or metal or ceramic powders in a build box.

Day Range sold:11.76-12.84

Komatsu Ltd

Japanese company denominated in yen on tokyo stock exchange,hence,we will skip this

Do note that most of the shares sold by ARK invest is due to profit-taking or rebalancing and most of the shares brought by ARK Invest is due to seeing the potential in the company

Thanks for reading! Remember to dyodd! 

*All company information are taken from Reuters and the historical price data from m.investing

No comments:

Post a comment